Diakonos Oncology
PrivateLast Round
Grant
Nov 19, 2025
Total Funding Raised
$38.56M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Diakonos Oncology operates in Healthcare & Life Sciences and is based in Houston, Texas. Its latest recorded funding round was a Grant round in November 2025.
Diakonos Oncology is a biotechnology company that develops a clinical-stage immunotherapy platform intended to focus on treating aggressive cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diakonos Oncology Comparables
Compare Diakonos Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AiVita Biomedical | 88% | |
| CellxLife | 87% | |
| Guardian Bio | 84% |
For institutional investors. Book with your work email.
Diakonos Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 19, 2025 | ||||
| SAFE | May 30, 2025 | ||||
| Seed | Aug 26, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Diakonos Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Buttonwood Group Advisors | SAFE |
| Cancer Prevention and Research Institute of Texas | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Monthly visitors increased 129% MoM, reaching 3K.
- Mar 18, 2026
Will attend ANN 2026 to showcase clinical data for DOC1021.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 3, 2026
Diakonos Oncology Corp. attends the 31st Annual Meeting & Education Day of the Society for Neuro-Oncology in Pennsylvania in Nov '26, where an abstract on DOC1021 clinical experience is selected for rapid oral and poster presentations.
For institutional investors. Book with your work email.
Diakonos Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Diakonos Oncology's valuation, stock price, and market status.
Is Diakonos Oncology a public or private company?
Diakonos Oncology is a private company.
What is the current stock price of Diakonos Oncology?
Diakonos Oncology is a private company, so its shares have no public market price. Caplight tracks Diakonos Oncology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Diakonos Oncology worth (valuation)?
Valuation information for Diakonos Oncology is not publicly available.
Can I buy Diakonos Oncology stock?
Diakonos Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Diakonos Oncology's last funding round?
Diakonos Oncology's most recent funding round was Grant on November 19, 2025.
Who are the main investors in Diakonos Oncology?
Key investors in Diakonos Oncology include Buttonwood Group Advisors, Cancer Prevention and Research Institute of Texas.
Will Diakonos Oncology IPO soon?
No public IPO plans have been announced for Diakonos Oncology.
How can I track Diakonos Oncology secondary market activity?
Caplight tracks bids, offers, and trades in Diakonos Oncology's shares on secondary markets.